My ePortfolio Register   

Promising myeloma agents in phase II trials

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.03.17
Views: 982

Dr Ruben Niesvizky - New York Presbyterian Hospital-Weill Cornell Medical Center, New York, USA

Dr Niesvizky speaks with ecancer at the 16th International Myeloma Workshop about promising agents in phase II trials for the management of myeloma.

He discusses the difficulty of integrating new agents into new molecules, and the challenge that patients face when trying to select effective drugs for their treatment.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence